Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crossref DOI link: https://doi.org/10.1007/s40268-017-0194-8
Published Online: 2017-06-30
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vergara-Dangond, Cristina
Sáez Belló, Marina
Climente Martí, Mónica
Llopis Salvia, Pilar
Alegre-Sancho, Juan José
Funding for this research was provided by:
CELLTRION Healthcare Co., Ltd, Incheon, Republic of Korea
License valid from 2017-06-30